Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Journal of Obesity & Metabolic Syndrome
Clinical trial data showed patients taking oral Wegovy lost an average of 13.6% of body weight at 71 weeks, while comparable injectable GLP-1 trials have shown average weight loss to be between 15% to 20%
In particular, participants taking the highest dose of Tirzepatide 15mg had a 5.6 percent reduction in total cholesterol, a 22.5 percent reduction in triglycerides, a 7.9 percent reduction in low-density lipoprotein (LDL) sterols, a 21.8 percent reduction in very low-density lipoprotein (VLDL) cholesterol, and a 10.8 percent increase in high-density lipoprotein (HDL) cholesterol
Includes All Blood Work, Visits, Medications & Supplies
Starting your Wegovy weekly injection can feel like a big step
Yes, but many patients choose to continue occasionally for energy support, maintenance, or to prevent metabolic backslide
